Adma Biologics (NASDAQ: ADMA) reported Q1 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on Adma Biologics (ADMA) click here.